Forum Replies Created
-
Posts
-
Thank you to everyone who’s taken part in today’s discussion. The live session officially concludes at 12pm, but the Sotas team will continue responding to all of today’s questions, so please stay with us, or if you need to leave, check back later today.
Thank you to Tom, Matt and David at Sotas for their time and support.
If you’d like to follow up directly, you’re very welcome to contact the Sotas team at info@sotas.co.uk
Thanks for questions so far! The Sotas team are working behind the scenes to craft their responses and will be back to you shortly.
Welcome to Sotas and any members joining us this morning to put their questions to today’s ‘Ask the Experts’ David and Matt.
We’ve also heard from some members, that since Brexit, getting timely or consistent regulatory advice across markets has become even harder. From Sotas’ perspective, what’s the smartest way for companies to navigate these differing UK and EU requirements – especially for those operating in both regions?
Many Medilink members tell us their biggest challenge is simply navigating the complexity of evolving regulations, especially when guidance feels open to interpretation.
From your experience at Sotas, what practical steps can smaller medtech or life sciences companies take to stay compliant without stalling innovation or burning through limited resources?
